Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 50(TM)

Rhea-AI Summary

Aytu BioPharma, Inc. (NASDAQ:AYTU) announced its recognition as the 178th fastest-growing company in North America by the Deloitte Technology Fast 500, demonstrating a remarkable 758% growth from 2017 to 2020. This accolade reflects Aytu's evolution into a fully integrated pediatric-focused specialty pharmaceutical company. CEO Josh Disbrow highlighted the company's strategic milestones and ongoing commitment to developing innovative therapeutic solutions. Aytu's commercial portfolio includes treatment for ADHD and other pediatric conditions, along with a developing pipeline for rare diseases.

Positive

• Ranked 178th on Deloitte's Technology Fast 500, indicating significant growth.
• Achieved a remarkable 758% revenue growth from 2017 to 2020.
• Evolving into a fully integrated pediatric-focused specialty pharmaceutical company.
• Strong commercial portfolio including products for ADHD and pediatric health.

Negative

• None.

ENGLEWOOD, CO / ACCESSWIRE / November 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced it ranked 178 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 27^th year. Aytu BioPharma grew 758% during this period.

"We are pleased to be recognized among an elite group of 500 innovative companies in Deloitte's Technology Fast 500™," said Josh Disbrow, Chief Executive Officer of Aytu BioPharma. "We have accomplished a significant amount over the last year, evolving into a fully integrated, pediatric-focused, specialty pharmaceutical company and we look forward to continuing to grow in the years ahead. We have many value-creating milestones on the horizon from our late-stage development pipeline and commercial business which we believe will continue to solidify our leadership position in this space."

About the 2021 Deloitte Technology Fast 500™

Now in its 27th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies - both public and private - in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2017 to 2020.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About Aytu BioPharma, Inc.

Aytu BioPharma is a specialty pharmaceutical company with a growing commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. Aytu markets ADHD products Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING. The company's other pediatric products include Karbinal® ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency. The company's evolution has been driven by strategic in-licensing, acquisition-based transactions and organic product growth. Aytu is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome (vEDS), a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. There are no currently approved treatments for vEDS. To learn more, please visit aytubio.com.

Contact:

Sarah McCabe
Stern Investor Relations
212-362-1200
sarah.mccabe@sternir.com

SOURCE: Aytu BioPharma, Inc.

View source version on accesswire.com:
https://www.accesswire.com/673339/Aytu-BioPharma-Ranked-Number-178-Fastest-Growing-Company-in-North-America-on-the-2021-Deloitte-Technology-Fast-50TM

FAQ

What did Aytu BioPharma announce on November 17, 2021?

Aytu BioPharma announced it ranked 178 on the Deloitte Technology Fast 500, with a growth of 758% from 2017 to 2020.

What is the significance of the Deloitte Technology Fast 500 for Aytu BioPharma?

The Deloitte Technology Fast 500 recognizes Aytu BioPharma for its rapid growth and innovation within the technology and life sciences sectors.

What are Aytu BioPharma's main products?

Aytu BioPharma primarily markets prescription products for ADHD, including Adzenys XR-ODT and Cotempla XR-ODT, along with other pediatric health products.

How much did Aytu BioPharma grow during the Deloitte Technology Fast 500 evaluation period?

Aytu BioPharma grew 758% during the evaluation period from 2017 to 2020.

Who is the CEO of Aytu BioPharma, and what did he say about the company’s future?

Josh Disbrow is the CEO of Aytu BioPharma; he expressed optimism about the company’s future growth and upcoming milestones.